Patient P-02059

Synthetic patientMETA-24 · Day 176 · 35–44 · F · baseline S03Steering view · 3D Open companion preview

Therapy response

Unstable

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

81%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S03
Day 63 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 68 SC-12 recommended — Supportive Compound SC-12
Day 69 Patient accepted — Started SC-12 in the companion
Day 75 GI symptom burden −14% vs expected — Supportive Compound SC-12
Day 79 GI-04 recommended — GI Support Protocol GI-04
Day 80 Patient declined — Not now
Day 81 Tolerance state changed — Unstable → Improving
Day 81 ME-01 recommended — Monitoring Escalation ME-01
Day 82 Patient accepted — Started ME-01 in the companion
Day 85 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 63.

Primary contributors, last 14 days

Nutritional resilience-5
GI instability-3
Toxicity+3
Treatment adherence+2

What helped?

Supportive Compound SC-12Day 68
Result: symptom burden −14%
GI Support Protocol GI-04Day 79
Declined by patient
Monitoring Escalation ME-01Day 81
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
86% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

78 min

stable · -0.1 vs previous 14 d

Sleep duration

Wearable

6.5 h

stable · +0.2 vs previous 14 d

Energy level

Daily log

3/10

worsening · -0.2 vs previous 14 d

Steps

Wearable

7,679

stable · -247 vs previous 14 d

GI burden

Companion

63.2/100

stable · +0.3 vs previous 14 d

Adherence

Companion

46.9 %

stable · -1.1 vs previous 14 d

Sleep quality

Wearable

29.2/100

improving · +3.0 vs previous 14 d

Glucose, CGM daily mean

CGM

137 mg/dL

stable · +2.5 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 19 from the failing basin, 71 from restoration.

Would help

GI-04 GI Support Protocol
74% improved among 66 similar · onset 8 d · confidence 96%
NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 79%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 79%
More protein
GI -6.5 next day on high-intake days · n 25

Would not help

Keep ultra-processed low
GI +6.7 next day on high-intake days · n 17
Keep histamine low
GI +6.6 next day on high-intake days · n 23
Keep fat low
GI +5.8 next day on high-intake days · n 23

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Ultra-processed food
+6.7detractor · 95%
Histamine load
+6.6detractor · 95%
Protein
-6.5supporter · 95%
Dietary fat load
+5.8detractor · 95%
Insoluble fibre
+4.7detractor · 95%
Alcohol
-2.2no signal · 46%
Simple carbohydrates
-0.7no signal · 15%
Caffeine
+0.6no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 63 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 29/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 62
Drug metabolism and exposure ↑20
- BloodToxicity index 45

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Intermediate metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 3.1 · butyrate capacity 29/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 49 ms
Sleep: 6.7 h
Steps: 6,459
Resting HR: 68 bpm

Daily log: GI score 63, nutritional resilience 36, adherence 47.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02326	49%	S18	NP-02	improved	44
P-02628	49%	S14	SC-12	improved	47
P-02657	49%	S14	—	—	42
P-02224	48%	S14	NP-02	no change	33
P-02546	47%	S20	NP-02	improved	40
P-02018	46%	S01	GI-04	improved	46
P-02253	45%	S14	NP-02	no change	41
P-02316	45%	S14	GI-04	improved	51
P-02506	45%	S14	SC-12	no change	32
P-02516	45%	S14	SC-12	improved	51
P-02348	44%	S14	GI-04	improved	49
P-02535	44%	S14	SC-12	improved	50